Solid Biosciences (SLDB) Competitors $4.85 -0.46 (-8.66%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SLDB vs. LOGC, CSBR, CRON, EOLS, RAPP, PLRX, ERAS, PRTA, REPL, and CRGXShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include LogicBio Therapeutics (LOGC), Champions Oncology (CSBR), Cronos Group (CRON), Evolus (EOLS), Rapport Therapeutics (RAPP), Pliant Therapeutics (PLRX), Erasca (ERAS), Prothena (PRTA), Replimune Group (REPL), and CARGO Therapeutics (CRGX). Solid Biosciences vs. LogicBio Therapeutics Champions Oncology Cronos Group Evolus Rapport Therapeutics Pliant Therapeutics Erasca Prothena Replimune Group CARGO Therapeutics LogicBio Therapeutics (NASDAQ:LOGC) and Solid Biosciences (NASDAQ:SLDB) are both small-cap retail/wholesale companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking. Do analysts prefer LOGC or SLDB? Solid Biosciences has a consensus target price of $15.14, indicating a potential upside of 212.22%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Is LOGC or SLDB more profitable? Solid Biosciences has a net margin of 0.00% compared to LogicBio Therapeutics' net margin of -141.03%. Solid Biosciences' return on equity of -58.75% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LogicBio Therapeutics-141.03% -81.98% -52.13% Solid Biosciences N/A -58.75%-47.84% Does the MarketBeat Community favor LOGC or SLDB? Solid Biosciences received 173 more outperform votes than LogicBio Therapeutics when rated by MarketBeat users. Likewise, 68.39% of users gave Solid Biosciences an outperform vote while only 64.08% of users gave LogicBio Therapeutics an outperform vote. CompanyUnderperformOutperformLogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% Solid BiosciencesOutperform Votes26468.39% Underperform Votes12231.61% Which has more risk & volatility, LOGC or SLDB? LogicBio Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Do insiders & institutionals believe in LOGC or SLDB? 46.1% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 8.1% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, LOGC or SLDB? Solid Biosciences has lower revenue, but higher earnings than LogicBio Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLogicBio Therapeutics$287M0.58-$317M-$5.79-1.10Solid Biosciences$8.09M23.96-$96.01M-$3.04-1.60 Does the media refer more to LOGC or SLDB? In the previous week, Solid Biosciences had 25 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 26 mentions for Solid Biosciences and 1 mentions for LogicBio Therapeutics. LogicBio Therapeutics' average media sentiment score of 0.00 beat Solid Biosciences' score of -0.06 indicating that LogicBio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment LogicBio Therapeutics Neutral Solid Biosciences Neutral SummarySolid Biosciences beats LogicBio Therapeutics on 15 of the 19 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.81M$2.91B$5.07B$8.66BDividend YieldN/A1.79%5.09%4.06%P/E Ratio-1.6043.08101.9417.40Price / Sales23.96217.681,197.2969.07Price / CashN/A178.0140.9636.36Price / Book1.164.096.335.87Net Income-$96.01M-$42.42M$119.64M$225.66M7 Day Performance-17.38%-10.63%-5.13%-1.34%1 Month Performance-23.26%-5.81%-2.72%1.15%1 Year Performance88.72%24.19%31.06%24.02% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences3.21 of 5 stars$4.85-8.7%$15.14+212.2%+78.3%$193.78M$8.09M-1.60100Analyst ForecastAnalyst RevisionNews CoverageLOGCLogicBio Therapeutics0.4212 of 5 stars$6.39+1.6%N/AN/A$167.73M$287M-1.1062CSBRChampions Oncology4.2027 of 5 stars$4.50+0.9%N/A-16.8%$61.16M$50.15M-17.31143Short Interest ↓News CoveragePositive NewsCRONCronos Group1.8775 of 5 stars$2.01-2.9%N/A+7.5%$768.42M$87.24M-15.46356Short Interest ↓Analyst RevisionNews CoverageEOLSEvolus4.1004 of 5 stars$12.11+1.9%N/A+34.3%$766.81M$202.09M-13.31170Short Interest ↑RAPPRapport Therapeutics1.5547 of 5 stars$20.95-4.7%N/AN/A$766.27MN/A0.00N/ANews CoveragePLRXPliant Therapeutics3.7369 of 5 stars$12.43-3.3%N/A-7.9%$756.42M$1.58M-3.7290ERASErasca2.8145 of 5 stars$2.67-5.0%N/A+20.3%$754.88MN/A-3.22126Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePRTAProthena1.7428 of 5 stars$14.01-13.0%N/A-59.4%$753.86M$133.35M-5.65173Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageREPLReplimune Group3.9974 of 5 stars$10.80-5.3%N/A+4.7%$738.94MN/A-3.54210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCRGXCARGO Therapeutics1.7566 of 5 stars$16.00-5.9%N/A+8.5%$736.45MN/A-3.76116Earnings ReportAnalyst ForecastNews Coverage Related Companies and Tools Related Companies LogicBio Therapeutics Competitors Champions Oncology Competitors Cronos Group Competitors Evolus Competitors Rapport Therapeutics Competitors Pliant Therapeutics Competitors Erasca Competitors Prothena Competitors Replimune Group Competitors CARGO Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLDB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
